Publications in Peer Reviewed Journals

1. Keerthana CK, Rayginia TP, Kalishwaralal Kalimuthu, Sandhini S, Haritha Nair, Amrutha Nisthul, M Swetha, Aiswarya US, Lekshmi R. Nath, Sanjay S V, Arun V, Jannet S, Shirly J, Aparna JS, Archana P, Vishnu SJ, Sankar Sundaram, NP Anto, TK. Maiti, C Sadasivan, Noah Isakov, Ravi SL, Harikumar KB and **Ruby John Anto***, (2026), Uttroside B, a US FDA-designated 'Orphan Drug', mitigates the development of hepatocellular carcinoma and its pulmonary metastasis via EGFR/ ERK-mediated inhibition of SREBP-1 and STAT-3. **Cell Death Discovery** DOI: https://doi.org/10.1038/s41420-026-03055-5. (Impact Factor 10.4)
2. Rayginia TP, Keerthana CK, Aiswarya US, Sadiq SC, Jannet S, Sanjay SV, Maria Joy , M Swetha, Shirly J, Aparna J S, Yadu Vijayan , Archana PR , Lekshmi R Nath, Kalishwaralal Kalimuthu, Vishnu Sunil J, Sankar Sundaram, NP Anto, Noah Isakov, Harikumar KB, Ravi SL and **Ruby John Anto***, (2026) Orphan drug Uttroside B Impedes NASH Progression and HCC Development in Experimental Models. **Journal of Hepatology Reports**. vol. 8; 1–15 DOI: https://doi.org/10.1016/j.jhepr.2025.101626. (Impact Factor 8.7)
3. Sadiq SC, Joy MP, Aiswarya SU, Ajmani A, Keerthana CK, Rayginia TP, Isakov N, **Ruby John Anto***. Unlocking nature's pharmacy: an in-depth exploration of phytochemicals as potential sources of anti-cancer and anti-inflammatory molecules. **Exploration of Drug Science**. 2024 Oct 30;2(6):744-84.
4. AS Achutha, S Krishna, VL Pushpa, D Harshini, US Aiswarya, S Nagarajan, **Ruby John Anto**, BS Vinod, Praveen Prakash, SV Manoj, KB Manoj, S Sarithamol, Suchitra Surendran, V Divya. Designing JAK2 Inhibitors Beyond Myeloproliferative Neoplasms-Theoretical and Experimental Analysis for Solid Cancers. **Chemistry Select 9** (19), e202400072
5. Keerthana CK, Aiswarya US, Rayginia TP, Yadu V, Shirley J, Shifana CS, Sankar S, D.K. Induja, Ravi S. Lankalapalli, Kuzhuvelil B Harikumar and **Ruby John Anto***. (2024). A novel combinatorial regimen involving sorafenib and uttroside B, a US FDA-designated 'Orphan drug', for the treatment of hepatocellular carcinoma. **Anti-Cancer Agents In Medicinal Chemistry** 10.2174/0118715206316190240527160242
6. Tennyson P. Rayginia, Keerthana CK, Sadiq C. Shifana, Sreekumar U. Aiswarya, Retnakumari P. Archana, Maria Joy P., Ravi S. Lankalapalli, Kuzhuvelil B. Harikumar and **Ruby John Anto***. (2024) Evaluation of Uttroside B, a potent bioactive from Solanum nigrum Linn, as a candidate drug molecule against non-alcoholic fatty liver disease. **Biomedicine**. Mar 4;44(1):65-70
7. Kalishwaralal K, Nazeer AA, Induja DK, Keerthana CK, Shifana SC, **Ruby John Anto**. Enhanced extracellular vesicles mediated uttroside B (Utt-B) delivery to Heptocellular carcinoma cell: Pharmacokinetics based on PBPK modelling. **Biochemical and Biophysical Research Communications**. 2024 Feb 11:149648.
8. Rayginia TP, Keerthana CK, Shifana CS, Maria PJ, Abhishek A and **Ruby John Anto***. (2024) Phytochemicals as Potential Lead Molecules against Hepatocellular Carcinoma. **Current Medicinal Chemistry.**doi:10.2174/0109298673275501231213063902
9. Shahbazi, R., Kalishwaralal, K., Paul, M.K. and **Ruby John Anto.,** 2023. Role of Extracellular vesi cles (EVs) in pathogenesis, diagnosis, therapeutic delivery, treatment, and theranostic applications in Cancer. **Frontiers in Bioengineering and Biotechnology**, 11, p.1288806.
10. Varma SS, Aiswarya SU, Keerthana CK, Rayginia TP, Induja DK, **Ruby John Anto**, Lankalapalli RS. Putative role of uttronin (degalactotigonin) in cytotoxicity of uttroside B in HepG2 cells. **Tetrahedron Letters**. 2023 Sep 1;127:154668.
11. Pouliquen DL, Trošelj KG, **Ruby John Anto**. Curcuminoids as Anticancer Drugs: Pleiotropic Effects, Potential for Metabolic Reprogramming and Prospects for the Future. **Pharmaceutics**. 2023 May 29;15(6):1612.
12. Mohan Shankar G., Aiswarya,US, Keerthana, CK, Rayginia, TP. and **Ruby John Anto*** (2023), Targeting Receptor Tyrosine Kinase Signalling: Avenues in the Management of Cutaneous Squamous Cell Carcinoma, **ISCIENCE**, DOI: https://doi.org/10.1016/j.isci.2023.106816. (Impact Factor: 6.107)
13. Faisal MA, Aiswarya US, Remya Johny, Meghna Sudhesh, Amrutha A. Nisthul, Ravi S. Lankalapalli, **Ruby John Anto*** and Smitha V. Bava* (2023), A potent bioactive fraction against colon cancer from Plectranthus vettiveroides, **Exploration of Targeted Anti-tumor Therapy**,4:227 239 DOI:https://doi.org/10.37349/etat.2023.00131.
14. Keerthana CK, Rayginia TP, Shifana SC, Anto NP, Kalimuthu K, Isakov N and **Ruby John Anto*** (2023) The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment. **Frontiers in Immunology**. 14:1114582. DOI: 10.3389/fimmu.2023.1114582 (Impact Factor: 8.786)

15. Shabna A, Jayesh Antony, Vinod V, Minakshi Saikia, Liju VB, Archana PR, Amrutha Nisthul, Vijai V Alex, Swetha M, Aiswarya US, Jannet S, Uma Subramanian Unni, Sankar Sundaram, DaisyR Sherin, Nikhil P Anto, Smitha VB, Sadasivan C, Sophia Ran, and **Ruby John Anto*** (2022), Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis, **Cellular and Molecular Life Science**, , DOI: https://doi.org/10.1007/s00018-022-04476-y; 79:478 (Impact Factor:9.261).
16. Aiswarya US, Gowda Vikas, Haritha H Nair, Liju, VB, Shabna A, Swetha M, Rayginia TP,Keerthana CK, Lekshmi R Nath, Reshma MV, Sankar Sundaram, Nikhil P Anto , Ravi Shankar Lankalapalli*, **Ruby John Anto*** and Smitha V Bava* Cucurbitacin B, purified and characterized from the rhizome of *Corallocarpus epigaeus* exhibits anti-melanoma potential, **Frontiers in Oncology**, 2022, DOI: 10.3389/fonc.2022.903832 ,.(Impact Factor: 6. 244)
17. Swetha M, Keerthana CK., Rayginia TP, Lekshmi R Nath, Haritha H Nair, Shabna A, Kalishwaralal Kalimuthu, Arun Kumar T, Aiswarya US, Jannet S, Sreekumar Pillai, K B Harikumar, Sankar Sundaram, Nikhil P Anto, Dee H Wu, Ravi Shankar Lankalapalli, Rheal Towner, Noah Isakov, Sathyaseelan S. Deepa and **Ruby John Anto***, Augmented efficacy of uttroside B over sorafenib in a murine modelof human hepatocellular carcinoma, **Pharmaceuticals**,2022, 15, 636. DOI: https://doi.org/10.3390/ph15050636 (Impact Factor: 5.68)
18. Lekshmi R Nath, Swetha M, Vinod V, Arun Kumar T, Haritha H Nair, Shabna A, Aiswarya,US, Rayginia,TP, Keerthana CK, Kalishwaralal Kalimuthu, Sankar Sundaram, Ravi Shankar Lankalapalli, Sreekumar Pillai, Rheal Towner, Noah Isakov and **Ruby John Anto*(**2022)**,** Blockade of uttroside B-induced autophagic pro- survival signals augments its chemotherapeutic efficacy against hepatocellular carcinoma, **Frontiers in Oncology,** 12:812598. DOI: 10.3389/fonc.2022.812598. (Impact Factor: 6. 244)
19. Mohan Shankar G, Swetha M, Keerthana CK, Rayginia TP and **Ruby John Anto*** (2022), Cancer Chemoprevention: A strategic approach using phytochemicals. **Frontiers in Pharmacology**, 2022, 12:812598.DOI: 10.3389/fonc.2022.812598. (Impact Factor: 5. 81)
20. Kalimuthu K, Keerthana CK, Mohan M, Arivalagan J, Christyraj JR, Firer MA, Choudry MH, **Ruby John Anto*** and Lee YJ***(**2021),The emerging role of selenium metabolic pathways in cancer: New therapeutic targets for cancer. **Journal of Cellular Biochemistry**. DOI: https://doi.org/10.1002/jcb.30196. (Impact Factor : 4.237)
21. Haritha H Nair, Akbar Nawab, Vinod V, Nikhil P Anto, VB Liju, Vijai V Alex, Amrutha Nisthul A,Aiswarya US, Swetha M, BS Vinod, Sankar Sundaram, Maria V Guijarro, Thomas Herlevich, Nesteena K N, Smitha V B, Sadasivan C, Maria Zajac-Kaye and **Ruby John Anto* (**2021), Targeting thymidylate synthase enhances the chemosensitivity of triple-negative breast cancertowards 5-FU- based combinatorial therapy, **Frontiers in Oncology,** DOI:10.3389/fonc.2021.656804 (Impact Factor: 6. 244)
22. Amrutha Nisthul A, Archana PR, **Ruby John Anto** and C Sadasivan* (2021) Virtual screening- based identification of novel fatty acid synthase inhibitor and 1 evaluation of its antiproliferative activity in breast cancer cells, **Journal of Molecular Graphics and modeling**, DOI:: 10.1016/j.jmgm.2021.107903 (Impact Factor: 2.942).
23. Mohan Shankar G , Vijai V Alex , Amrutha Nisthul A , Smitha V Bava , Sankar Sundaram , Archana P Retnakumari , Sadasivan Chittalakkottu and **Ruby John Anto*** (2020**) ,** Pre clinical evidences for the efficacy of Tryptanthrin as a potent suppressor of skin cancer, DOI: 10.1111/cpr.12710. **Cell Proliferation**, 53(1): e12710. (Impact Factor:8.755).
24. Atreyi Biswas, Irene M Roy, Prathibha C Babu, Javed K Manesia, Sarah Schouteden, Vinod Vijayakurup, Ruby John Anto, Joerg Huelsken, Adam Lacy-Hulbert, Catherine M Verfaillie and *Satish Khurana (2020), Periostin/Integrin-pool in the fetal Liver, Stem Cell Reports, , DOI: 10.1016/j.stemcr.2020.06.022 (Impact Factor: 7.765).
25. Bhagyalakshmi Nair, **Ruby John Anto**, M Sabitha and Lekshmi R Nath* (2020), Kaempferol- mediated sensitization enhances chemotherapeutic efficacy of sorafenib against hepatocellular carcinoma: An *in silico* and *in vitro* Approach, **Advanced Pharmaceutical Bulletin**, , 10 (3), 472- 476. (Impact Factor: 2.31)
26. Amrutha Nisthul A, Archana P R, Mohan Shankar G, **Ruby John Anto*** & C. Sadasivan***** (2019), Pyridine derivatives as anticancer lead compounds with Fatty Acid Synthase as the target: An *in silico*- guided *in vitro* study. **Journal of Cellular Biochemistry** (DOI: 10.1002/jcb.28923). (Impact Factor: 4.237).
27. Vinod V, Arunkumar TT, Mohan Shankar G, Archana P.R. Devika Nandan, Jannet S, Jayesh Antony, Vijai VA, BS.Vinod1,VB Liju, Sankar S, GS Vinod Kumar, and **Ruby John Anto*** (2019), Chitosan Encapsulation Enhances the Bioavailability and Tissue Retention of Curcumin and Improves its in Preventing B[a]P-induced Lung Carcinogenesis. **Cancer PreventionResearch**, Published Online February 13, 2019; DOI: 10.1158/1940-6207.CAPR-18-0437. (Impact Factor: 4.02).
28. Amrutha Nisthul A., Archana P. Retnakumari, Shabna A., **Ruby John Anto** & C. Sadasivan. In silico screening for identification of fatty acid synthase inhibitors and evaluation of their antiproliferative activity using human cancer cell

lines. **Journal of Receptors and Signal Transduction, 2018,** Sep 26:1-7. doi: 10.1080/10799893.2018.1511730. (Impact Factor: 2.2).

29. Minakshi Saikia, Archana P.R, Shabna A, NP Anto, Rashmi Mittal, Shabna S, Kavya S Pillai, B S.Vinod, Vidya Peter, Reeba Thomas and ***Ruby John Anto**, Heteronemin, a marine natural product, sensitizes acute myeloid leukemia cells towards cytarabine chemotherapy by regulating farnesylation of Ras, **Oncotarget**, 2018, 9, 18115-18127 (Impact Factor: 5.168).
30. Arun Kumar TT, Archana.P.R, Mohan Shankar, Vinod V, Shabna A, Sanu Thankachan, Kavya S Pillai, Jisha J Pillai, Vijai V Alex, Teena Jacob Chirayil, GS Vinod Kumar & *Ruby John Anto (2017), Folic acid Conjugation improves the Bioavailability and Chemosensitizing efficacy of Curcumin- encapsulated PLGA-PEG Nanoparticles towards Paclitaxel Chemotherapy, Oncotarget Impact Factor: 5.168
31. Lekshmi R. Nath, Jaggaiah N. G, Arun Kumar TT, Vinod V, Shabna S, Shabna A, Sophia M. Joseph, Jayesh Antony, K S Veena, Sankar Sundaram, Udaya K. Marelli, *****Ravi S. Lankalapalli &**Ruby John Anto*(**2016**),** Evaluation of uttroside B, a saponin from Solanum nigrum Linn, as a promising chemotherapeutic agent against hepatocellular carcinoma. **Scientific Reports** *6:36318 doi: 10.1038/srep36318***,** Impact Factor: 5.228.
32. Lekshmi R. Nath, S. N. Kumar, Arya A. Das, Bala Nambisan, A. Shabna, *****C Mohandas and ***RubyJohn Anto*** 2016, *In vitro* evaluation of the antioxidant, 3,5-Dihydroxy-4-ethyl-trans-stilbene(DETS) isolated from Bacillus cereus as a potent candidate against malignant melanoma. **Frontiers in Microbiology**, 7:452, doi: 10.3389/fmicb.2016.00452,. Impact factor: 5.64.
33. Smitha V Bava, Arun Kumar TT, Sreekanth CN and **Ruby John Anto*** (2016), Cervical cancer: A comprehensive approach towards extermination. **Annals of Medicine**, 48(3):149-61. doi: 10.3109/07853890.2016.1145796.. Impact factor: 4.709
34. Shamina Azeez*, Jayesh Antony, N.K. Leela and **Ruby John Anto** (2016)**,** Antioxidant andcytotoxic effects of essential oil, water and ethanol extracts of major Indian spices **Indian J. Hort**. 73(2),: 229-237**.**
35. Vineshkumar TP, Arun Kumar TT, Vijayakurup V, Antony J, Bava SV, Anwar S, Sundaram S, and **Ruby John Anto* (**2015). Curcumin inhibits B[a]PDE-induced procarcinogenic signals in lung cancer cells, and curbs B[a]P-induced mutagenesis and lung carcinogenesis. **BioFactors,** 41, 431 442,. (Impact factor: 4.734).
36. Lekshmi R. Nath, Jaggaiah N. Gorantla, Sophia M Joseph, Jayesh A, Sanu T, Darsan B. M, S. Sankar, Ravi S. L and **Ruby John Anto* (**2015**),** Kaempferide, the most active among the four flavonoids isolated and characterized from Chromolaena odorata, induces apoptosis in cervical cancer cells while being pharmacologically safe. **RSC Adv., 5, 100912.** Impact factor:3.84.
37. Jayesh Antony, Minakshi S, Vino T. C, Nishanth Kumar S and **Ruby John Anto*** (2015). Sesbania: A prospective candidate to be excavated for anticancer drugs. **The Natural Products Journal,** 5(4): 273-287, DOI: 10.2174/1872211310999151110155644,..
38. Jayesh Antony, Minakshi S, Vinod.V, Lekshmi. R. Nath, Mohana Rao K, M.S.R. Murty, Anju Paul,Shabna A, Harsha Ch, Sophia M J, Nishanth KS, Elizabeth J P, Sriramya IV, Sridivya IV, Sophia Ran, Sankar S, Easwary R and **Ruby John Anto* * (**2015). DW-F5: A novel formulation against malignant melanoma from *Wrightia tinctoria*, **Scientific Reports,** 5:11107, DOI: 10.1038/srep11107, Impact Factor: 5.228.
39. Jisha J. Pillai, Arun Kumar TT, **Ruby John Anto,** Devika Nandan, N. Ashwanikumar and GS Vinod Kumar*. Curcumin entrapped folic acid conjugated PLGA PEG nanoparticles exhibit enhanced anticancer activity by site specific delivery, ***RSC Adv.***,5, 25518-25524. 2015. Impact Factor: 3.708.
40. Vinod BS, Haritha H Nair, Vijayakurup V, Shabna A, Shah S, Krishna A, Pillai KS, Thankachan S, and **Ruby John Anto* (**2015). Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2-Akt axis. **Cell Death Discovery.** 2015; 1:15061. doi: 10.1038/cddiscovery..61. (Impact Factor: 5.241).
41. Haritha HNair and Ruby John Anto* (2015) Triple negative breast cancer: The therapeutic

windows yet to be opened? Science Letters, 4 (175). ISSN 2454 7239.

42. Radhakrishnan E K, Smitha V B, Sai Shyam N, Lekshmi R Nath, Arun Kumar T T, Soniya E V and**Ruby John Anto***. [6]-Gingerol induces caspase-dependent apoptosis and prevents PMA-induced proliferation in colon cancer cells by inhibiting MAPK/AP-1 signaling, ***PLOS ONE***, 9(8): e104401. doi:10.1371, 2014. Impact Factor: 3.73.
43. Jisha J Pillai, Arun Kumar T T, **Ruby John Anto**, Devika Nandan Chithralekha, Ashwanikumar Narayanan, and G S Vinod Kumar (2014). Folic acid conjugated cross-linked acrylic polymer (FA- CLAP) hydrogel for site specific delivery of hydrophobic drugs to cancer cells, ***J Nanobiotechnology***. 12: 25. Impact Factor:4.08.
44. S Nishanth Kumar, Sreerag Ravikumar Sreekala, Dileep Chandrasekaran, Bala Nambisan and **RubyJohn Anto (**2014**.** Biocontrol of Aspergillus Species on peanut kernels by antifungal diketopiperazine producing Bacillus cereus associated with entomopathogenic nematode. **PLOS ONE**, 9(8): e106041. doi:10.1371, , Impact Factor 3.73.
45. M. Sreelekha, NP Anto, **Ruby John Anto** and PM Shafi. Cytotoxicity of acetonyl dihydro chelerythrin,arnottianamide and 6-(2.hydroxy propyl)-dihydro chelerythrine towards human cancer cell lines , ***Ind. J. Chem. Sec.B***, 647-651, 2014 Impact Factor 0.648.
46. Jaggaiah N. Gorantla, Jamsheena Vellekkatt, Lekshmi R.Nath, **Ruby John Anto** and Ravi S. Lankalapalli*(2014).Cytotoxicity studies of semi-synthetic derivatives of theveside derived fromthe aqueous extract of leavesCerbera odollam, ***Natural Product Research,*** DOI: 10.1080/14786419.2014.913242,. Impact Factor: 1.031.
47. Kumar SN, Nambisan Bala, Sundaresan A, Mohandas C and **Ruby John Anto**, Isolation and identification of antimicrobial secondary metabolites from Bacillus cereus associated with a rhabditid entomopathogenic nematode. ***Ann Microbiol***., 64, 209 218, 2014. Impact Factor: **1.56**.
48. M. S. R. Murty, Raju Penthala, Lekshmi R. Nath and **Ruby John Anto (**2014**),** Synthesis of Salicylic Acid-Based 1, 3, 4-Oxadiazole Derivatives Coupled with Chiral Oxazolidinones: Novel Hybrid Heterocycles as Antitumor Agents ***Letters in Drug Design & Discovery***, 11, 1-10, 10.2174/15701808116661406270046O7, Impact Factor: 0.961.
49. Kumar SN, Nambisan B, Kumar BS, Vasudevan NG, Mohandas C, Cheriyan VT and **Ruby John Anto** (2013), Antioxidant and anticancer activity of 3,5-dihydroxy-4-isopropylstilbene produced by Bacillus sp. N strain isolated from entomopathogenic nematode. ***Arch Pharm Res***. DOI: 10.1007/s12272-013-0207-2. Impact factor: 1.538.
50. P.Jyothi, T.Shalina Begum, UCA.Jaleel, N.P.Anto, **Ruby John Anto** and PM.Shafi*, Synthesis and biological evaluation of some novel imidazolinones, ***Int J Pharm Biomed Sci***, 2013, 4(2), 78-82.
51. BS Vinod, J Antony, HH Nair, VT Puliyappadamba, M Saikia, S Shyam Narayanan, A Bevin and **Ruby John Anto*** (2013). Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. ***Cell Death and Disease*** 4, e505; doi:10.1038/cddis.2013.26,. Impact Factor 6.04.
52. BS Vinod, Tessy T Maliekal and **Ruby John Anto*** (2013), Phytochemical As Chemosensitizers: From Molecular Mechanism to Clinical Significance. Comprehensive Invited Review. ***Antioxidants& Redox Signaling***. 18, 1307 1348, Impact Factor: 8.456.
53. M. S. R. Murty, B. Ramalingeswara Rao, Mohana Rao Katiki, Lekshmi R. Nath & **Ruby John Anto**, (2013) Synthesis of piperazinyl benzothiazole/benzoxazole derivatives coupled with 1,3,4 oxadiazole-2-thiol: novel hybrid heterocycles as anticancer agents. ***Med Chem Res***., 22, 4980- 4991,. Impact Factor: 1.6**.**
54. Deepa G, Arun Kumar T Thulasidasan, **Ruby John Anto**, J Jisha Pillai, GS Vinod Kumar.(2012) Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy. ***Int J. Nanomedicine,***7, 4077 - 4088,. Impact Factor: 3.130.
55. Lekha Nair K, Arun Kumar TT, Deepa G, **Ruby John Anto**, GS Vinod Kumar. Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier. ***Int J Pharm*.**4:425 (1-2), 44-52, 2012. Impact Factor:3.607.
56. M. S. R. Murty*, B. Ramalingeswara Rao, Kesur R. Ram, J. S. Yadav, Jayesh Antony and **RubyJohn Anto** (2011). Synthesis and preliminary evaluation activity studies of novel

4- (aryl/heteroaryl-2-ylmethyl)-6-phenyl-2-[3-(4-substituted-piperazine-1-yl)propyl] pyridazin-3(*2H*)-one derivatives as anticancer agents. ***Med Chem Res***. 21, 3161-3169. Impact Factor: 1.271.

57. P. L. Anto, Ruby John Anto, Hema Tresa Varghese, C. Yohannan Panicker, Daizy Philip*, Gustavo F.S. Andrade, Alexandre G. Brolo. Spectroscopic investigations and computational study of sulfur trioxide pyridine complex. J. Raman Spectrosc. 42, 1812 1819, 2011. Impact Factor: 3.137.
58. CN Sreekanth, Smitha V Bava, E Sreekumar and **Ruby John Anto*** (2011)**.** Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. ***Oncogene.*** 30, 3139-3152,. Impact Factor: 7.414.
59. M.S.R. Murty, Kesur R. Ram, Rayudu Venkateswara Rao, J.S. Yadav, Janapala Venkateswara Rao,Vino. T. Cheriyan and **Ruby John Anto** (2011)**..** Synthesis and preliminary evaluation of 2- substituted- 1,3-benzoxazole and 3-[(3-substituted)propyl]-1,3-benzoxazol- 2(3*H*)-one derivatives as potentanticancer agents. ***Med Chem Res.*** 20:576 586,. Impact Factor: 1.271.
60. Smitha V Bava, Chanickal N Sreekanth, Arun Kumar T Thulasidasan, Nikhil P Anto, Vino T Cheriyan, Vineshkumar T Puliyappadamba, Sajna G Menon, Santhosh D Ravichandran, and Ruby John Anto* (2011).. Akt is upstream and MAPKs are downstream of NF-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int J Biochem Cell Biol. 43, 331-341. Impact Factor: 4.99.
61. Vineshkumar TP**,** Vino T Cheriyan**,** Arun Kumar T Thulasidasan**,** Smitha V Bava**,** Balachandran S Vinod**,** Priya R Prabhu**,** Ranji Varghese**,** Arathy Bevin**,** Shalini Venugopal and ***Ruby John Anto**(2010)**..** Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. ***Molecular Cancer***, 9, 220,. (Highly Accessed). Impact Factor: 5.134.
62. KP Laladhas, Vino T Cheriyan, Vineshkumar TP, Smitha V Bava, Rajesh G Unnithan, Parvathy L Vijayammal and **Ruby John Anto*** (2010)**...** A novel protein fraction from Sesbania grandiflora induces apoptosis in cancer cells and shows potential anticancer and chemopreventive efficacy *in vivo.* ***J Cellular and Mol. Med.*** 14, 636-646, 2010. Impact Factor: 6.8.
63. Sanalkumar R, Indulekha C L , Divya T S, Divya M S , **Ruby John Anto,** Vinod B, Vidyanand S, Jagatha B, Shalini V and Jackson James***.** ATF2 maintains a subset of neural progenitors through CBF1/Notch independent Hes-1 expression and synergistically activates the expression of Hes-1 in Notch dependent neural progenitors. ***J. Neurochem.*** 113, 807-818, 2010. Impact Factor: 4.480.
64. M. D. Ajitha Bai , D. P. N. Nair , T. L. Gayathri , K. P. Padmakumaryamma, **Ruby John Anto,** G. Jayakumar , Ajaikumar and R. Rajasree**.** Chemical composition and bioactivities of volatile components from the seed and bark oils of *Litsea coriaceae* Hook. f., Lauraceae. ***International Journal of Essential Oil Therapeutics*** 4, 1-4, 2010.
65. P. L. Anto, **Ruby John Anto**, HT Varghese, C Y Panicker and Daizy Philip. Vibrational spectroscopic studies and *ab initio* calculations of phenyl phosphate disodium salt. ***J. Raman Spectrosc.*** 41, 113-119, 2010. Impact Factor: 3.147.
66. Rajendran G*, Amritha C S, **Ruby John Anto** and Vino T Cheriyan. Synthesis, thermal andantitumor studies of thorium (IV) complexes with furan-2- aldehyde-*N*-phenyl thiosemicarbazone**.** ***J. Serb. Chem. Soc.*** 75, 1-13, 2010. Impact Factor: 0.725
67. P. L. Anto, **Ruby John Anto**, H. T. Varghese, C. Y. Panicker, D. Philip*, and A. G. Brolo. (2009) FT- IR, FT-Raman and SERS spectra of Anilinium Sulfate: ***J. Raman Spectrosc.,*** 40,1810-15. Impact Factor:3.147.
68. Manickam Venkatraman, **Ruby John Anto**, Asha Nair, Merina Varghese and Devarajan Karunagaran* (2005) Biological and chemical inhibitors of NF- - induced apoptosis:***Mol. Carcinogenesis***, *44:51*-59.
69. Smitha V. Bava**,** Vineshkumar T. Puliappadamba, Ayswaria Deepti, Asha Nair, Devarajan Karunagaran, and **Ruby John Anto*** (2005) Sensitization of taxol-induced apoptosis by curcumin involves down regulation of NF-κB and Akt and is independent of tubulin polymerization: ***J. Biol. Chem.,*** 280: 6301 - 6308. Impact Factor: 5.854.
70. Tessy Thomas Maliekal, **Ruby John Anto** and D. Karunagaran* (2004) Differential activation of Smads in HeLa and SiHa cells that differ in their response to transforming growth factor-β: ***J. Bio. Chem.,*** 279: 36287 92. Impact Factor: 6. 355.

71. Suby Oommen, **Ruby John Anto**, Srinivas G and Karunagaran D*. (2004) Allicin (from garlic) induces caspase- mediated apoptosis in cancer cells: ***European. J. Pharmaco****l*., 485,97-103. ImpactFactor: 2.432.
72. Srinivas G, Ruby John Anto, Priya Srinivas, S Vidhyalaksmi, V Priya Senan and D Karunagaran D*. (2003) Emodin induces apoptosis of human cervical cancer cells through poly (ADP-ribose) polymerase cleavage and activation of caspases-9: European.J.Pharmacol., 473, 117-25. Impact Factor: 2.352.
73. **Ruby John Anto**, Manickam Venkatraman and Devarajan Karunagaran* (2003**)** Inhibition of N F- sensitizes A431 Cells to Epidermal Growth Factor- induced Apoptosis whereas its activation by ectopic expression of RelA confers resistance: ***J. Biol.Chem.,*** 278, 25490-98. Impact Factor: 6. 482.
74. **Ruby John Anto**, Asok Mukhopadyay, Sisir Sishodia, Gary C. Gyrola and Bharat Aggarwal*. (2002) Cigarette Smoke Condensate Activates Nuclear Transcription Factor- B Through Phosphorylation and Degradation of : Its Role in Induction of Cyclooxygenase-2: ***Carcinogenesis,*** 23, 1511-18. Impact Factor: 5. 404
75. **Ruby John Anto**, Asok Mukhopadyay, Kate Denning and Bharat B. Aggarwal* (2002) Curcumin (Diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome C Release: Its Suppression by ectopic expression of Bcl-2 and Bcl-xL: ***Carcinogenesis,***23, 143-150. Impact Factor: 5. 404.
76. **Ruby John Anto**, Tessy T Maliekal and Devarajan Karunagaran* (2000) L-929 Cells Harboring Ectopically Expressed Rel A Resist Curcumin- induced Apoptosis: ***J. Biol Chem.,*** 275, 15601-604 Impact Factor: 7.368.
77. **Ruby John Anto**, Girija Kuttan, Dinesh Babu KV, Rajasekharan KN and Kuttan R*. (1998) Anti-inflammatory activity of natural and synthetic curcuminoids: ***Pharm. Pharmacol. Commun.*** , 4, 103- 106.
78. **Ruby John Anto**, Josely George, Dinesh Babu KV, Rajasekharan KN and Kuttan R*. (1996) Antimutagenic and anticarcinogenic activities of natural and synthetic curcuminoids: ***Mutation Res.,*** 370, 127- 131.
79. **Ruby John Anto**, Girija Kuttan, Dinesh Babu KV, Rajasekharan KN and Kuttan R*. (1996) Synthetic curcuminoids as anticancer agents and as free radical scavangers: ***Int. J. Pharm.***, 131, 1- 8.
80. **Ruby John Anto**, Girija Kuttan, M.N. A. Rao, V. Subbaraju and Ramadasan Kuttan* (1995) Anticancer and antioxidant activity of synthetic chalcones and related compounds: ***Cancer Letters***, 97, 33-37.
81. **Ruby John Anto**, Girija Kuttan, Dinesh Babu KV, Rajasekharan KN and Kuttan R*. (1995) Antitumor and antioxidant activity of curcuminoids: ***Cancer Letters***, 94, 79-83.
82. **Ruby John Anto**, Girija Kuttan, Ramadasan Kuttan*, Kota Satyanarayana and M.N. A. Rao, (1994) Tumor reducing and antioxidant activities of sydnone substituted chalcones: ***J. Clin. Biochem.and Nutr***.,17, 73- 80

***Corresponding author**

<u>Non-Peer Reviewed Journals</u>

1. Archana P R, Shabna S and ***Ruby John Anto**. Hepatocellular carcinoma: An overview, **Amala Research Bulletin** (2017) 37, 13-20.
2. Lekshmi.R.Nath, Ravi Shankar L and *Ruby John Anto. In vitro and in vivo evaluation of the anticancer potential of SN2, a spirostan-3-ol derivative identified and characterized from Solanum nigrum against hepatocellular carcinoma, Proceedings of 28th Kerala Science Congress,: 330-341, 2016
3. Mohan Shankar G and *__Ruby John Anto__. Role of Hedgehog signaling in basal cell carcinoma, ***Amala Research Bulletin*** (2014) 34, 115-121
4. Minakshi Saikia and *__Ruby John Anto__. Acute myeloid leukemia: Causes, diagnosis, classification and treatment modalities. ***Amala Research Bulletin*** (2013) 33, 147-154.
5. Haritha H Nair and *__Ruby John Anto__. Triple negative breast cancer: The unusual one among the many. ***Amala Research Bulletin*** (2012) 32, 100-108.
6. Arun Kumar TT and *__Ruby John Anto__, Nanotechnology and its applications in the field of medicine. ***Amala Research Bulletin*** (2011) 31, 144-154.
7. Lekshmi. R Nath and **Ruby John Anto**, General approaches towards extraction of medicinal plants. ***Amala Research Bulletin*** (2010)30, 150-158.
8. Deepa I, Vino T Cheriyan and *__Ruby John Anto__. An overview of protein kinase B/Akt signaling in cancer. ***Amala Research Bulletin*** (2009) 29, 19-26.

9. Jayesh Antony and *__Ruby John Anto__ (2008). A molecular approach to skin cancer. ***Amala Research Bulletin***, 28, 141-152.
10. Priya R Prabhu and *__Ruby John Anto__ (2007) Molecular pathogenesis of colorectal cancer ***Amala Research Bulletin***, 27, 212-230.
11. Vinod BS and * __Ruby John Anto__ (2006) Human Epidermal Growth factor receptor signaling as a therapeutic target in breast cancer ***Amala Research Bulletin***, 26, 18-27.
12. CN Sreekanth and *__Ruby John Anto__ (2005) Cervical cancer -The risk factors and Treatment modalities ***Amala Research Bulletin***, 25, 81-92.
13. Smitha Bava, Vineshkumar TP and *__Ruby John Anto__ **(**2005). Molecular mechanism behind the synergistic effect of Taxol and curcumin. ***Proceedings of 17th Kerala Science Congress*** 75-77.
14. Vineshkumar.TP, Smitha Bava and *__Ruby John Anto__ (2005) Curcumin down-regulates Nicotine resistance in lung cancer cells ***Indian Journal of Medical Researc. (supplement)***, 100
15. Vineshkumar.TP and *__Ruby John Anto__ (2004) Cigarette Smoking and Lung Cancer: Environmental and Molecular Implications. ***Amala Research Bullettin***, 24, 31-41
16. Smitha VB and *__Ruby John Anto__ (2003) Antiapototic proteins as targets of chemotherapy. ***Amala Research Bullettin***, 23, 1-6.
17. *__Ruby John Anto__, Karunagaran D and Smitha VB (2003) Curcumin potentiates taxol induced apoptosis of cervical cancer cells: ***Proceedings of Kerala Science Congress***, 15, 263- 268.

Chapters in Text Books

1. **Ruby John Anto** Smitha V.B., Vinesh Kumar T.P., Sreekanth C.N., Vinod B.S., Vino T. C, Priya Prabhu and Gayathri L.T. Phenolics of the functional food Curcumin- A nutraceuticals with potential chemosensitive – Pharma Med Press. 2008. p-202-208.

2. CN Sreekanth, Smitha VB, Arun Kumar TT, N P Anto, VT Cheriyan, Vineshkumar TP, SG Menon, SD Ravichandran and *__Ruby John Anto__ - Curcumin: A Potent Candidate to be Evaluated as a Chemosensitizer in Paclitaxel Chemotherapy Against Cervical Cancer. In: Perspectives in Cancer Prevention-Translational Cancer Research. P Sudhakaran P, Oommen V, Pillai, MR (Eds.). Pubd: Springer; 2014 edition (October 25, 2013) pp 21-43.

3. Mohan Shankar G., #Jayesh Antony and ***Ruby John Anto**- Quercetin and Tryptanthrin: Two Broad Spectrum Anticancer Agents for Future Chemotherapeutic Interventions, In: ENZ 37, Mechanism of the anticancer effect of phytochemicals. Fuyu Tamanoi (Ed) Chapter Number:1, Pubd. Elsevier Inc., June 2015 ISSN 1874-6047 . http://dx.doi.org/10.1016/bs.enz.2015.05.001, (#equal authorship).

4. #Jayesh Antony, #Minakshi Saikia and ***Ruby John Anto**. Phytochemicals from Fruits and Vegetables as potential anti-cancer agents: special reference to skin cancer. In: Anticancer properties of fruits and vegetables: A scientific review. Ajay Kunnummakkara (Ed). Pubd: World Scientific Publishing Co.; 2014edition, pp 277-307 (#equal authorship)

5. Haritha H. Nair, Vijai V. Alex and ***Ruby John Anto**. Significance of nutraceuticals in cancer therapy. In: Evolutionary Diversity as a Source for Anticancer Molecules, Academic Press, 2021, Pages 309- 321,ISBN 9780128217108.

6. Archana P Retnakumari and ***Ruby John Anto**. Application of nano-drug delivery systems in improving the therapeutic efficacy of bioactive natural products, In: Advanced Pharmaceutical Herbal Nanoscience, 2022, *Part I,* Bentham Science Publishers Pte. Ltd., Pp: 104-132 (29),Doi: 10.2174/9789815036510122010008.

7. Haritha H Nair and ***Ruby John Anto**. Etiological insights into TNBC and their related catastrophic risks. In: Therapeutic drug targets and phytomedicine, 2023, Bentham Science Publishers Pte. Ltd., Pp: 1- 25.

8. B S Vinod and ***Ruby John Anto**, Herbal medicine: prejudice to realm of reality against TNBC. In: Therapeutic drug targets and phytomedicine, 2023, Bentham Science Publishers Pte. Ltd., Pp: 123-138.

9. Tennyson P. Rayginia[#], Keerthana CK[#], Anwar Shabna, Sreekumar U. Aiswarya, Sadiq C. Shifana and **Ruby John Anto***. (2024). Phytochemicals as Potential Lead Molecules in Cancer Drug Research and Development. **In: Traditional Medicines in Drug Discovery and Development.** (pp-286-317) Cambridge Scholars Publishing.

10. Kalishwaralal K, Ajmani Abhishek, Keerthana CK, Rayginia TP, Swetha M, Aiswarya US, Jaison A, Smitha VB, Michael A Firer and **Ruby John Anto**. (2023). Selenium Metabolic Pathway in Ferroptotic Cell Death. **In: Tang, D. (eds) Ferroptosis in Health and Disease.** Springer, Cham. https://doi.org/10.1007/978-3-031-39171-2_17

*** Corresponding Author**